One complication associated with previously prescribed chemotherapy regimens is cardiotoxicity, which can prove to be dose limiting. Although newer agents (e.g. the tyrosine kinase inhibitors) are now widely used, the cardiac safety profile of these drugs has as yet not been systematically assessed. Researchers have recently investigated the cardiac safety of nilotinib and imatinib , drubs that are used for the treatment of chronic myeloid leukaemia. In a small cohort study, 11 patients were followed for a period of one year, all remainign in functional NYHA class I classification, , with no difference in the biomarkers evaluated (cystatin-C and NT-proBNP) and no change in systolic or diastolic function, evaluated by echocardiography. Further multi-center studies are required. More here.
Initial evidence suggests that tyrosine kinase inhibitors appear to be free from cardiotoxicity
Oct 1, 2018